Article
Cell & Tissue Engineering
Joanie Hare, Paulina Garcia DeLeon, Krystle Pool, Donna Reioux, Milford Fontenot, Richard E. Champlin, Erin N. Eaton, David Marin, Katayoun Rezvani, Elizabeth J. Shpall, Jeffrey M. Wilson, Chitra Hosing
Summary: The success of umbilical cord blood transplant depends on the dose of total nucleated and CD34+ cells infused, highlighting the importance of collecting high-quality cord blood units with high cell doses. Maternal gestational age and race, and neonatal weight and sex were found to correlate with the total nucleated cell dose, emphasizing the impact of these factors on cell dose. Optimized collection of umbilical cord blood is crucial for its use as a source of stem cells for transplantation.
Article
Pediatrics
Alessandra Coscia, Giovanni Boscarino, Maria Di Chiara, Francesca Faccioli, Roberto Pedicino, Elisa Onesta, Antonella Giancotti, Violante Di Donato, Benedetta Ronchi, Francesca Zantonelli, Alessia Russo, Chiara Mezzapiastra, Gianluca Terrin
Summary: The study demonstrates the effectiveness of a natural dermo-protective powder containing extract of Arnica montana in reducing cord detachment time, improving parents' stress levels, and reducing the risk of complications in newborns.
EUROPEAN JOURNAL OF PEDIATRICS
(2021)
Review
Cell & Tissue Engineering
Yufeng Xi, Guang Yue, Shuqiang Gao, Rong Ju, Yujia Wang
Summary: Perinatal brain injury is a major cause of death and disability in children. Transplantation of human umbilical cord blood mononuclear cells has shown significant efficacy and safety in animal and clinical trials for the treatment of perinatal brain injury.
STEM CELL RESEARCH & THERAPY
(2022)
Review
Cell & Tissue Engineering
Gabriela Sanchez-Petitto, Katayoun Rezvani, May Daher, Hind Rafei, Partow Kebriaei, Elizabeth J. Shpall, Amanda Olson
Summary: Umbilical cord blood transplantation is an attractive alternative source of hematopoietic stem cells, with unique immune tolerance and engraftment kinetics. It has a lower risk of GvHD and comparable clinical outcomes to bone marrow transplantation. However, limitations in cell numbers and delayed engraftment pose challenges for its wider application. Research is being conducted to address these limitations and explore the potential of cord blood in treating various disorders.
STEM CELLS TRANSLATIONAL MEDICINE
(2023)
Article
Clinical Neurology
Ping Wang, Xiaonan Du, Quanli Shen, Wenjin Jiang, Chen Shen, Hongsheng Wang, Shuizhen Zhou, Yi Wang, Xiaowen Qian, Xiaowen Zhai
Summary: The study analyzed the efficacy of unrelated umbilical cord blood transplantation (UCBT) in the treatment of hereditary leukodystrophy. The results showed that UCBT can improve survival rates and stabilize neurological function in patients with hereditary leukodystrophy.
FRONTIERS IN NEUROLOGY
(2022)
Article
Biophysics
Stephanie Vairy, Isabelle Louis, Marie-France Vachon, Johanne Richer, Pierre Teira, Sonia Cellot, Edith Villeneuve, Elie Haddad, Michel Duval, Henrique Bittencourt
Summary: Intrabone cord blood transplantation (IB UCBT) is safe and well-tolerated in children with malignant and non-malignant hematologic diseases, providing faster hematologic recovery compared to traditional IV UCBT. A clinical trial showed a 6-year event-free survival rate of 66.7% and an overall survival rate of 80% with IB UCBT.
BONE MARROW TRANSPLANTATION
(2021)
Review
Cell & Tissue Engineering
Zhongjie Sun, Bing Yao, Huangfan Xie, XunCheng Su
Summary: The application of umbilical cord blood (UCB) as a source of hematopoietic stem and progenitor cells (HSPCs) has grown worldwide in the past 30 years. UCB has advantages of rapid donor availability, less strict HLA-matching demands, and low rates of graft-versus-host disease (GVHD). However, the limited number of HSPCs within a single UCB unit poses challenges for wide clinical application. Strategies to improve UCB engraftment have been developed, focusing on increasing HSPC numbers and enhancing HSPC homing to the recipient BM niche.
STEM CELLS TRANSLATIONAL MEDICINE
(2022)
Article
Chemistry, Multidisciplinary
Hongfu Cao, Manyu Chen, Xiaolin Cui, Yuan Liu, Yuhan Liu, Siyan Deng, Tun Yuan, Yujiang Fan, Qiguang Wang, Xingdong Zhang
Summary: This study suggests that exosomes derived from umbilical cord-derived mesenchymal stem cells (UCMSC-EXOs) combined with chondrocyte-targeting capacity and controlled-release system have the potential for osteoarthritis (OA) treatment by rejuvenating aging chondrocytes. The research identified the essential miRNAs within UCMSC-EXOs and the p53 signaling pathway as a key factor. By engineering the exosomes on membranes and encapsulating them in hyaluronic acid microgels, a two-phase releasing system was formed, which synergistically facilitated the repair of OA cartilage in a rat model. Overall, this study highlights the rejuvenating effects of UCMSC-EXOs on OA chondrocytes and their potential for future cell-free OA treatment when combined with chondrocyte-targeting and sustained-release strategies.
Article
Cell & Tissue Engineering
Meijuan Tu, Aijie Huang, Lijuan Ning, Baolin Tang, Chunli Zhang, Guangyu Sun, Xiang Wan, Kaidi Song, Wen Yao, Ping Qiang, Yue Wu, Xiaoyu Zhu
Summary: The study established a predictive model combining clinical and nutritional factors to predict overall survival in UCBT recipients. High-risk score, calf skinfold thickness, and low albumin level were associated with survival post-UCBT.
STEM CELL RESEARCH & THERAPY
(2023)
Article
Biochemistry & Molecular Biology
Eun Ah Ye, Ho Seok Chung, Yoonkyung Park, Jeong Hye Sunwoo, Whanseo Lee, Jin Kim, Hungwon Tchah, Hun Lee, Jae Yong Kim
Summary: This study demonstrated the differentiation of human umbilical cord-derived mesenchymal stem cells (UC-MSCs) into corneal endothelial cells (CECs). The efficacy of MSC-induced CEC injection was investigated in a rabbit model of corneal endothelial dysfunction (CED). The results showed that MSC-induced CEC injection improved corneal opacity and neovascularization in the rabbit model.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Cell & Tissue Engineering
Xiaoyu Zhu, Baolin Tang, Zimin Sun
Summary: Umbilical cord blood transplantation (UCBT) has been successfully used in clinics for over 30 years, offering advantages such as reliable source, ease of use, improved outcomes. Over time, UCBT has seen an increasing trend in Asia and China, while decreasing in the United States and Europe annually.
STEM CELLS TRANSLATIONAL MEDICINE
(2021)
Article
Oncology
Xin-Yu Li, Li-Ping Zhan, Dian-Dian Liu, Xia-Wei Han, Han Chen, Zheng-Zhou Wu, Yin Wang, Li-Ping Que, Xiao-Jun Wu, Su Liu, Kai-Mei Wang, Shao-Liang Huang, Jian-Pei Fang, Ke Huang, Hong-Gui Xu
Summary: Using posttransplant cyclophosphamide (PTCY) as a method for controlling peri-engraftment syndrome (PES) and prophylaxis against graft-versus-host disease (GvHD) in single-unit umbilical cord blood transplantation (UCBT) for children with acute leukemia is safe and effective. Higher doses of PTCY may be more suitable for GvHD prophylaxis in UCBT patients.
Review
Oncology
Jiasheng Wang, Leland Metheny
Summary: Cord blood is an important source for allogeneic hematopoietic cell transplantation and is also being developed for cell therapy products. The unique cellular composition of cord blood, including higher percentages of hematopoietic stem cells and progenitor cells, offers advantages in immune tolerance and off-the-shelf cell therapy development. In addition, cord blood-derived mesenchymal stem cells have potential in regenerative medicine and inflammatory/autoimmune conditions. This review focuses on recent clinical development of cord blood-derived therapies in oncology.
FRONTIERS IN ONCOLOGY
(2023)
Article
Immunology
XiaoJuan Lu, Hao Wang, Hongwei Wang, Fan Xie, Cuibao Jiang, Danpeng Shen, Hongpeng Zhang, Jie Yang, Youshu Lin
Summary: The study showed that both indirubin and human umbilical cord mesenchymal stem cells (hUC-MSCs) can effectively reduce psoriatic lesions in BALB/c mice, with the combined treatment showing the best results.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Cell & Tissue Engineering
Oldouz Shareghi-oskoue, Leili Aghebati-Maleki, Mehdi Yousefi
Summary: Premature ovarian failure (POF) is a problem for women before the age of 40, characterized by symptoms such as amenorrhea and low estrogen levels. The current treatment approach involves stem cell therapy, particularly HUCMSC transplantation, which has shown to effectively improve ovarian function and treat infertility.
STEM CELL RESEARCH & THERAPY
(2021)
